1. Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease
- Author
-
Janné Almeido-Hill, George R. Siber, Bonnie Zacher, G. Raymond Reid, Mathuram Santosham, Mark Wolff, and Claudette M. Thompson
- Subjects
Hyperimmune globulin ,Haemophilus Infections ,Globulin ,Immunoglobulins ,Meningococcal Vaccines ,Meningococcal vaccine ,Neisseria meningitidis ,complex mixtures ,Pneumococcal Infections ,Microbiology ,Pneumococcal Vaccines ,medicine ,Humans ,Immunology and Allergy ,Bacterial Capsules ,Haemophilus Vaccines ,biology ,business.industry ,Tetanus ,Diphtheria ,Polysaccharides, Bacterial ,Immunization, Passive ,Infant ,medicine.disease ,Antibodies, Bacterial ,Haemophilus influenzae ,Pneumococcal infections ,Streptococcus pneumoniae ,Infectious Diseases ,Immunization ,Bacterial Vaccines ,Immunology ,biology.protein ,bacteria ,Antibody ,business - Abstract
A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by greater than 0.15 microgram/ml within 4-6 h and by 2-4 micrograms/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligosaccharide-diptheria CRM197 conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.
- Published
- 1992
- Full Text
- View/download PDF